Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage in favor of Novo Nordisk A/S's ... a strong Q1 earnings report from Lilly and immediately raised concerns from ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound ... detention center Transgender issues are a strength for Trump ...

Zepbound's prescription ... struggles with supply issues in 2024. CVS's pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Zepbound’s prescription ... struggles with supply issues in 2024. CVS’s pharmacy benefit management unit, the largest in the U.S., said it would drop Zepbound coverage from July 1, but keep ...

LLY has delivered impressive returns of 15% year-to-date (as of April 30), outperforming the S&P 500’s 5% decline during the ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Factors such as cost, insurance coverage, and supply issues may affect your ability to get Zepbound. Zepbound is FDA-approved to help with weight loss in adults who are obese or overweight and ...